Global Cetuximab Biosimilar Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Cetuximab Biosimilar Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Cetuximab Biosimilar report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Cetuximab Biosimilar market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029. Demand from Metastatic colorectal cancer and Metastatic breast cancer are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Cetuximab Biosimilar industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029.
Globally, Cetuximab Biosimilar key manufacturers include Actavis, Amgen, Celltrion, Pfizer, Bio X Cell, Wuhan Dima Biotechnology and Guangdong ANNPO Biotechnology, etc. Actavis, Amgen, Celltrion are top 3 players and held % sales share in total in 2022.
Cetuximab Biosimilar can be divided into 100 mg/50 mL Injection and 200 mg/100 mL Injection, etc. 100 mg/50 mL Injection is the mainstream product in the market, accounting for % sales share globally in 2022.
Cetuximab Biosimilar is widely used in various fields, such as Metastatic colorectal cancer, Metastatic breast cancer, Non-small cell lung cancer and Other, etc. Metastatic colorectal cancer provides greatest supports to the Cetuximab Biosimilar industry development. In 2022, global % sales of Cetuximab Biosimilar went into Metastatic colorectal cancer filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Cetuximab Biosimilar market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Actavis
Amgen
Celltrion
Pfizer
Bio X Cell
Wuhan Dima Biotechnology
Guangdong ANNPO Biotechnology
Segment by Type
100 mg/50 mL Injection
200 mg/100 mL Injection
Metastatic colorectal cancer
Metastatic breast cancer
Non-small cell lung cancer
Other
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Cetuximab Biosimilar market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Cetuximab Biosimilar, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Cetuximab Biosimilar industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Cetuximab Biosimilar in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Cetuximab Biosimilar introduction, etc. Cetuximab Biosimilar Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Cetuximab Biosimilar market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
North America, Europe and Asia Pacific are the key regions for Cetuximab Biosimilar industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029.
Globally, Cetuximab Biosimilar key manufacturers include Actavis, Amgen, Celltrion, Pfizer, Bio X Cell, Wuhan Dima Biotechnology and Guangdong ANNPO Biotechnology, etc. Actavis, Amgen, Celltrion are top 3 players and held % sales share in total in 2022.
Cetuximab Biosimilar can be divided into 100 mg/50 mL Injection and 200 mg/100 mL Injection, etc. 100 mg/50 mL Injection is the mainstream product in the market, accounting for % sales share globally in 2022.
Cetuximab Biosimilar is widely used in various fields, such as Metastatic colorectal cancer, Metastatic breast cancer, Non-small cell lung cancer and Other, etc. Metastatic colorectal cancer provides greatest supports to the Cetuximab Biosimilar industry development. In 2022, global % sales of Cetuximab Biosimilar went into Metastatic colorectal cancer filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Cetuximab Biosimilar market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Actavis
Amgen
Celltrion
Pfizer
Bio X Cell
Wuhan Dima Biotechnology
Guangdong ANNPO Biotechnology
Segment by Type
100 mg/50 mL Injection
200 mg/100 mL Injection
Segment by Application
Metastatic colorectal cancer
Metastatic breast cancer
Non-small cell lung cancer
Other
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Cetuximab Biosimilar market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Cetuximab Biosimilar, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Cetuximab Biosimilar industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Cetuximab Biosimilar in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Cetuximab Biosimilar introduction, etc. Cetuximab Biosimilar Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Cetuximab Biosimilar market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices